Nootropic Agents - Administration & dosage
Research News and Information

Sunday, November 22, 2009

Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation.

30 Aug 2009 Galantamine, a novel Alzheimer's drug, is known to inhibit acetylcholinesterase activity and potentiate nicotinic acetylcholine receptor (nAChR) in the brain. We previously reported that galantamine potentiates the NMDA-induced currents in primary ... Read more...

[Neuro-enhancement. Brain doping]

29 Jun 2009 Cognitive enhancement, the increase in the mental ability by psychoactive substances and other interventions has received a renewed boost through the development of innovative principle. More than 100 drugs are currently being developed, tested or ... Read more...

[Neuro-enhancement from an addiction specialist's viewpoint]

29 Jun 2009 The use of medications to enhance performance in healthy individuals is increasingly being propagated even by neuroscientists under such colorful terms as"neuro-enhancement". A large number of medications, including psychostimulants have been ... Read more...

Latest indexed articles for 'Nootropic Agents - Administration & dosage'

These are the very latest articles for this heading:

• Turbocharging the brain. 29 Sep 2009
• Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. 30 Aug 2009
• [Neuro-enhancement. Brain doping] 29 Jun 2009
• [Neuro-enhancement from an addiction specialist's viewpoint] 29 Jun 2009
• Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. 30 May 2009
• Electroencephalographic effects of galantamine in major depressive disorder. 30 May 2009
• Ethics in everyday pediatrics. 30 May 2009
• Cognitive-enhancing activity of loganin isolated from Cornus officinalis in scopolamine-induced amnesic mice. 25 May 2009
• Sequelae of closed craniocerebral trauma and the efficacy of piracetam in its treatment in adolescents. 29 Apr 2009
• Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. 29 Apr 2009
• A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia. 19 Apr 2009
• Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. 30 Mar 2009
• [Clinical observation on acupuncture combined with Yizhi Jiannao granules for treatment of Alzheimer's disease] 30 Mar 2009
• Long-term ginsenoside administration prevents memory impairment in aged C57BL/6J mice by up-regulating the synaptic plasticity-related proteins in hippocampus. 15 Mar 2009
• Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. 27 Feb 2009
• Characteristic effects of anti-dementia drugs on rat sleep patterns. 27 Feb 2009
• Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. 27 Feb 2009
• [Effects of anti-dementia drugs on sleep-wake patterns in sleep-disturbed rats] 30 Jan 2009
• Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. 28 Jan 2009
• Piracetam improves children's memory after general anaesthesia. 30 Dec 2008

See a longer list of these articles.

Technical information about 'Nootropic Agents'

Definition: Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.

Registry Number: 0

Descriptor UI: D018697

Alternative terms: Nootropic Agents; Agents, Nootropic; Nootropics; Cognitive Enhancers; Enhancers, Cognitive; Nootropic Drugs; Drugs, Nootropic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.427.637;

Online Note: use PSYCHOTROPIC DRUGS to search NOOTROPIC DRUGS 1990-94

History Note: 95; NOOTRPIC DRUGS was see PSYCHOTROPIC DRUGS 1990-94

Technical Notes: CNS agents; from Greek nous, mind; GEN or unspecified: prefer specifics